# Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

> **NCT02638909** · PHASE2 · TERMINATED · sponsor: **Criterium, Inc.** · enrollment: 4 (actual)

## Conditions studied

- Colorectal Adenocarcinoma
- Cholangiocarcinoma
- Pancreatic Adenocarcinoma
- Hepatocellular Adenocarcinoma
- Gastric Adenocarcinoma
- Esophageal Adenocarcinoma

## Interventions

- **DRUG:** ceritinib

## Key facts

- **NCT ID:** NCT02638909
- **Lead sponsor:** Criterium, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12
- **Primary completion:** 2018-03-29
- **Final completion:** 2018-03-29
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Lack of Enrollment
- **Last updated:** 2018-04-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02638909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02638909, "Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02638909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*